The case of a 39-year old woman with metachromatic leukodystrophy (MLD) is presented. In the clinical examination she revealed symptoms of a frontotemporal dementia without any signs of polyneuropathy. If frontotemporal dementia is diagnosed MLD should be excluded.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2007-980065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treating apathy in frontotemporal dementia.
Lancet Neurol
February 2025
Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications.
Lancet Neurol
February 2025
Department of Neurosciences, and Leuven Brain Institute, University of Leuven, Leuven, Belgium; Laboratory of Neurobiology, Center for Brain & Disease Research, VIB, Leuven, Belgium. Electronic address:
Autosomal dominant mutations in the gene encoding the DNA and RNA binding protein FUS are a cause of amyotrophic lateral sclerosis (ALS), and about 0·3-0·9% of patients with ALS are FUS mutation carriers. FUS-mutation-associated ALS (FUS-ALS) is characterised by early onset and rapid progression, compared with other forms of ALS. However, different pathogenic mutations in FUS can result in markedly different age at symptom onset and rate of disease progression.
View Article and Find Full Text PDFIntranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
Lancet Neurol
February 2025
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada; Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada. Electronic address:
Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings on the Neuropsychiatric Inventory over 1 week and, in a randomised, double-blind, placebo-controlled, crossover study, a single dose of 72 IU oxytocin increased blood-oxygen-level-dependent signal in limbic brain regions. We aimed to determine whether longer treatment with oxytocin improves apathy in people with frontotemporal dementia.
View Article and Find Full Text PDFDirect and Indirect Protein Interactions Link FUS Aggregation to Histone Post-Translational Modification Dysregulation and Growth Suppression in an ALS/FTD Yeast Model.
J Fungi (Basel)
January 2025
Department of Chemistry and Biochemistry, Brooklyn College, Brooklyn, NY 11210, USA.
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are incurable neurodegenerative disorders sharing pathological and genetic features, including mutations in the gene. FUS is an RNA-binding protein that mislocalizes to the cytoplasm and aggregates in ALS/FTD. In a yeast model, FUS proteinopathy is connected to changes in the epigenome, including reductions in the levels of H3S10ph, H3K14ac, and H3K56ac.
View Article and Find Full Text PDFA Novel CNN-Based Framework for Alzheimer's Disease Detection Using EEG Spectrogram Representations.
J Pers Med
January 2025
Department of Informatics and Telecommunications, University of Ioannina, Kostakioi, 47100 Arta, Greece.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that poses critical challenges in global healthcare due to its increasing prevalence and severity. Diagnosing AD and other dementias, such as frontotemporal dementia (FTD), is slow and resource-intensive, underscoring the need for automated approaches. To address this gap, this study proposes a novel deep learning methodology for EEG classification of AD, FTD, and control (CN) signals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!